This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Mild cognitive impairment (MCI) has emerged as an incipient stage of disease that defines the transition between normal aging and pathologic decline, with an elevated risk of progression to dementia. Despite consensus conferences to develop criteria for MCI, several limitations result in irregular application of these criteria and variability in outcomes. Rates of progression to dementia differ due to variations in population selection, follow-up interval, and operationalization of criteria. For example, diagnoses are generally highest in clinic-based samples (e.g., 15% per year) when compared to community samples (7.3% per year).1 An additional limitation to the concept of MCI is that it has been largely applied to Alzheimer disease (AD), neglecting the multiple other dementing conditions that can evolve from this early state of decline. One study demonstrated that more than 20% of patients with MCI with primary memory impairment progressed to non-AD such as dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, and vascular dementia.2 Progression of nonamnestic MCI is likely …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
